This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics

SAVINGS DEADLINE EXPIRES IN:

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
May 14-17, 2024 | In-Person + Digital
Boston, MA, USAHynes Convention Center

Kevin McDonnell, PhD
Vice President, Chemistry US at Bicycle Therapeutics
Speaker

Profile

Dr. Kevin McDonnell obtained his undergraduate degree at the University of New Brunswick and subsequently his Ph.D. in Biology and Chemistry at the Massachusetts Institute of Technology (MIT). He began his professional career developing synthetic peptides targeting the neonatal Fc receptor (FcRn) and therapeutic recombinant Fc fusion proteins at Syntonix Pharmaceuticals and Biogen. He then headed up the discovery chemistry efforts at BIND Therapeutics and drove the discovery of small molecule, peptide and protein-conjugated polymeric nanoparticles for targeted delivery of anti-cancer agents. Currently, as Vice President of Chemistry for Bicycle Therapeutics, Dr. McDonnell is responsible for advancing bicyclic peptide therapeutics in the oncology discovery programs.

Agenda Sessions

  • Bicycles as Modular and Precision Guided Anti-tumor Immune Cell Agonists

    8:45am